12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.

NCT00735007 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

106

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Rebif® New Formulation (RNF) using RebiSmartTM

Sponsor

EMD Serono